Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 ...

Arbutus Biopharma is stripping its workforce back to just a “core team” needed to oversee mid-stage trials of its potential functional cure for hepatitis B.

Baltimore County police have identified the remains of a man whose body was found in Arbutus.

Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Arbutus’ pipeline of internally ...

The Arbutus layoffs will result in a 40% reduction in the company’s workforce. Though steep, ABUS stock gained about 1% in the early afternoon session.

Immediately prior to the Transaction, Mr. Bull and Arbutus held beneficial ownership of, or control and direction over, 4,257,712 common shares of ADENTRA, representing approximately 19.0% of the then ...

Arbutus Biopharma and Roivant's patent infringement lawsuit against Moderna takes a positive turn. Read why we remain on the sidelines of ABUS stock for now.

With a new order clarifying several terms of the patents at the center of Arbutus Biopharma and Genevant Sciences’ infringement suit against Moderna, the companies are one step closer in | A ...

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.